# Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies

> **NCT03881774** · PHASE1 · UNKNOWN · sponsor: **Henan Cancer Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Refractory
- Relapsed
- B Cell Lymphoma
- B Cell Leukemia

## Interventions

- **BIOLOGICAL:** CAR-T cells

## Key facts

- **NCT ID:** NCT03881774
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-02-27
- **Primary completion:** 2021-01-31
- **Final completion:** 2022-01-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-03-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03881774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03881774, "Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT03881774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*